0001193125-22-309133.txt : 20221220 0001193125-22-309133.hdr.sgml : 20221220 20221220160603 ACCESSION NUMBER: 0001193125-22-309133 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221219 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221220 DATE AS OF CHANGE: 20221220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVITA Medical, Inc. CENTRAL INDEX KEY: 0001762303 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 202578762 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39059 FILM NUMBER: 221474791 BUSINESS ADDRESS: STREET 1: 28159 AVENUE STANFORD STREET 2: SUITE 220 CITY: VALENCIA STATE: CA ZIP: 91355 BUSINESS PHONE: 661-568-1317 MAIL ADDRESS: STREET 1: 28159 AVENUE STANFORD STREET 2: SUITE 220 CITY: VALENCIA STATE: CA ZIP: 91355 FORMER COMPANY: FORMER CONFORMED NAME: Avita Therapeutics, Inc. DATE OF NAME CHANGE: 20200630 FORMER COMPANY: FORMER CONFORMED NAME: Avita Medical, Ltd. DATE OF NAME CHANGE: 20181218 8-K 1 d434009d8k.htm 8-K 8-K
false 0001762303 0001762303 2022-12-19 2022-12-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 19, 2022

 

 

Avita Medical, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39059   85-1021707

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

28159 Avenue StanfordSuite 220Valencia, CA 91355   661.367.9170
(Address of principal executive offices, including Zip Code)   (Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   RCEL   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


Item 8.01.

Other Events.

On December 19, 2022, AVITA Medical, Inc. issued a press release announcing the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RECELL® System. The application, if approved, will expand the indication of RECELL to include the treatment of stable vitiligo. A copy of the press release is attached hereto as Exhibit 99.1.

The information under this Item 8.01 and in Item 9.01 below is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.

  

Description

99.1    AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 20, 2022

 

AVITA MEDICAL, INC.
By:  

/s/ Donna Shiroma

Name:   Donna Shiroma
Title:   General Counsel
EX-99.1 2 d434009dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo

 

VALENCIA, Calif., and MELBOURNE, Australia, December 19, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RECELL® System. The application, if approved, will expand the indication of RECELL to include the treatment of stable vitiligo.

“We are pleased to take the next step towards expanding the clinical application of RECELL into a treatment for vitiligo,” said Jim Corbett, AVITA Medical Chief Executive Officer. “RECELL offers first-in-class repigmentation of vitiligo lesions through the transplantation of melanocytes. Once approved, this indication will dramatically expand our reach in a huge market with limited treatment options. We anticipate a full launch of this treatment option in January 2025.”

This PMA application includes the recently released results of the pivotal trial for vitiligo. The study achieved its primary effectiveness endpoint of super-superiority (p<0.025). The study compared repigmentation success rates in treating patients with segmental and non-segmental stable vitiligo.

The RECELL System earned FDA Breakthrough Device designation for its proposed indication of vitiligo. Under the program, AVITA Medical will receive prioritized review and interactive communication with the FDA throughout the premarket review phase. The standard FDA review timeline for a PMA application is 180 days.

This PMA application follows the original PMA approval of the RECELL System in September 2018.

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

ABOUT VITILIGO

Vitiligo is a disease that attacks pigment-producing cells, called melanocytes, resulting in their destruction or malfunction. The result is a loss of pigmentation in patches of skin. Vitiligo affects up to 2% of the population worldwide,i including up to 6.5 million Americans,ii with an estimated 1.3 million suffering from stable vitiligo. Vitiligo has a comparable psychosocial impact to other major dermatology diseases including psoriasis (thick, scaly skin) and atopic dermatitis (red, cracked skin).iii,iv,v Like these diseases, those living with vitiligo may suffer from poor body image along with low self-esteem, leading to an impaired quality of life.vi

ABOUT AVITA MEDICAL, INC.

AVITA Medical® is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The RECELL® System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin cells. Delivered


at the point-of-care, RECELL enables improved clinical outcomes and validated cost savings. RECELL is the catalyst of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-in-class cellular therapies for multiple indications, including soft tissue repair and repigmentation of stable vitiligo lesions.

AVITA Medical’s first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is approved for acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. In February 2022, the FDA reviewed and approved the PMA supplement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow.

The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 15,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE—RECELL Autologous Cell Harvesting Device (https://recellsystem.com) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are approved under the RECELL System brand to promote skin healing in a wide range of applications including burns, soft tissue repair, vitiligo, and aesthetics. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

FOR FURTHER INFORMATION:

Investors & Media

AVITA Medical, Inc.

Jessica Ekeberg

Phone +1-661-904-9269

investor@avitamedical.com

media@avitamedical.com

 

 

i 

Picardo et al. Vitiligo. Nature Reviews Disease Primers. 2015.

ii 

John Harris, MD, PhD – Presentation as part of Incyte Corporate presentation. (Harris, UMass, is a global leader in Vitiligo; AVITA collaborator). https://investor.incyte.com/static-files/f72257b8-ea0a-484e-8644-9bdcc9694fe5

iii 

National Psoriasis Foundation – Statistics, https://www.psoriasis.org/psoriasis-statistics/ Accessed 10/5/2020.

iv 

The burden of vitiligo: Patient characteristics associated with quality of life. Homan, et al. JAAD. 2009.

v 

Comparison of the Psychological Impacts of Asymptomatic and Symptomatic Cutaneous Diseases: Vitiligo and Atopic Dermatitis.Noh, et al. Annals of Derm. 2013.

vi 

Willingness-to-pay and quality of life in patients with vitiligo. Radtke, et al. BJD. 2009.

EX-101.SCH 3 rcel-20221219.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rcel-20221219_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 rcel-20221219_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g434009g1220054035653.jpg GRAPHIC begin 644 g434009g1220054035653.jpg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�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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Dec. 19, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001762303
Document Type 8-K
Document Period End Date Dec. 19, 2022
Entity Registrant Name Avita Medical, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39059
Entity Tax Identification Number 85-1021707
Entity Address, Address Line One 28159 Avenue Stanford
Entity Address, Address Line Two Suite 220
Entity Address, City or Town Valencia
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91355
City Area Code 661
Local Phone Number 367.9170
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol RCEL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 8 d434009d8k_htm.xml IDEA: XBRL DOCUMENT 0001762303 2022-12-19 2022-12-19 false 0001762303 8-K 2022-12-19 Avita Medical, Inc. DE 001-39059 85-1021707 28159 Avenue Stanford Suite 220 Valencia CA 91355 661 367.9170 false false false false Common Stock, par value $0.0001 per share RCEL NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d434009d8k.htm d434009dex991.htm rcel-20221219.xsd rcel-20221219_lab.xml rcel-20221219_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d434009d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d434009d8k.htm" ] }, "labelLink": { "local": [ "rcel-20221219_lab.xml" ] }, "presentationLink": { "local": [ "rcel-20221219_pre.xml" ] }, "schema": { "local": [ "rcel-20221219.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rcel", "nsuri": "http://avitamedical.com/20221219", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d434009d8k.htm", "contextRef": "duration_2022-12-19_to_2022-12-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d434009d8k.htm", "contextRef": "duration_2022-12-19_to_2022-12-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20221219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-22-309133-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-309133-xbrl.zip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end